Literature DB >> 7945739

Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.

D D Miller1, M Flaum, S Arndt, F Fleming, N C Andreasen.   

Abstract

Although it is generally accepted that antipsychotic treatment improves the negative symptoms of schizophrenia in the context of improvement of positive symptoms, exactly how and to what extent they effect "primary" negative symptoms remains controversial. Antipsychotic treatment may reduce only those negative symptoms secondary to positive or depressive symptoms, and may have minimal, if any effect, on negative symptoms that represent a primary psychopathological trait manifestation of schizophrenia. In an effort to further examine this issue, we prospectively assessed negative, positive, depressive, and extrapyramidal symptoms following the discontinuation of antipsychotic medication. Fifty-nine DSM III-R schizophrenic patients underwent a three-week drug wash as part of our neuroimaging protocols. We assessed psychopathological status and adverse effects utilizing various rating instruments (i.e., Scale for Assessment of Positive Symptoms [SAPS], Scale for Assessment of Negative Symptoms [SANS], Hamilton Rating Scale for Depression, and Simpson-Angus Extrapyramidal) at baseline and weekly during this three-week period. Negative symptoms, as measured by the SANS, worsened significantly during the three-week drug wash. Positive symptoms showed a less consistent change with symptoms of disorganization worsening and with psychotic symptoms remaining the same. The changes in negative symptoms during the drug-free period were correlated with the changes in psychosis and disorganization, but not with changes in depression or extrapyramidal side effects. We were not able to substantiate if the worsening in negative symptoms was a direct result of the worsening of positive symptoms or if they were changing simultaneously, but independent of each other.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945739     DOI: 10.1038/npp.1994.31

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  6 in total

1.  Antipsychotics and amotivation.

Authors:  Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; George Foussias; Paul J Fletcher; Ofer Agid; Gary Remington
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

2.  Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Authors:  Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero
Journal:  Psychopharmacology (Berl)       Date:  2016-08-24       Impact factor: 4.530

3.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Loxapine in the treatment of schizophrenia : an open study.

Authors:  S A Emmanuel; H Naidu; V B Sovani
Journal:  Indian J Psychiatry       Date:  1997-07       Impact factor: 1.759

5.  Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.

Authors:  Mary E Kelley; Gretchen L Haas; Daniel P van Kammen
Journal:  Schizophr Res       Date:  2008-07-11       Impact factor: 4.939

Review 6.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.